4//SEC Filing
Bruno Lawrence 4
Accession 0000950170-25-001332
CIK 0001958086other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 5:00 PM ET
Size
8.4 KB
Accession
0000950170-25-001332
Insider Transaction Report
Form 4
Bruno Lawrence
DirectorChairman and CEO
Transactions
- Tax Payment
Common Stock
2024-12-31$17.31/sh−43,380$750,908→ 189,397 total - Exercise/Conversion
Common Stock
2024-12-31+69,574→ 232,777 total - Exercise/Conversion
Performance Shares
2024-12-31−69,574→ 0 totalExercise: $0.00→ Common Stock (69,574 underlying)
Footnotes (1)
- [F1]These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022. The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024.
Documents
Issuer
Core Laboratories Inc. /DE/
CIK 0001958086
Entity typeother
Related Parties
1- filerCIK 0001730336
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 5:00 PM ET
- Size
- 8.4 KB